Background
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia due to defects in insulin secretion, action, or both, leading to microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease) complications . The global burden of diabetes has escalated dramatically, with the International Diabetes Federation (IDF) estimating 536.6 million adults (10.5%) living with diabetes in 2021, a figure projected to rise to 783.2 million by 2045 . This epidemic is driven by aging populations, urbanization, and lifestyle factors such as sedentary behavior and obesity, with prevalence highest in high-income countries (11.1%) compared to low-income nations (5.5%) . Urban areas exhibit a 46% higher prevalence than rural settings (12.1% vs. 8.3%), reflecting environmental and socioeconomic determinants . Notably, nearly half of all adults with diabetes remain undiagnosed, underscoring gaps in screening and healthcare access .
Diagnostic criteria for diabetes were standardized by the World Health Organization (WHO) in 1998 and updated in subsequent consultations, with fasting plasma glucose (FPG) ≥7.0 mmol/L (126 mg/dL), 2-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) during an oral glucose tolerance test (OGTT), or HbA1c ≥6.5% serving as the primary thresholds . Intermediate states—impaired fasting glucose (IFG: FPG 6.1–6.9 mmol/L) and impaired glucose tolerance (IGT: 2-hour OGTT 7.8–11.0 mmol/L)—identify individuals at high risk for progression to diabetes . The metabolic syndrome, a cluster of cardiometabolic risk factors, is diagnosed when ≥3 of 5 components are present: elevated blood pressure, triglycerides, fasting glucose, low HDL cholesterol, and central obesity, with waist circumference serving as a preliminary screening tool . These diagnostic frameworks are critical for early intervention and risk stratification.
Current Evidence
Diagnosis and Screening
The WHO diagnostic criteria for diabetes are widely adopted, with HbA1c ≥6.5% providing a convenient, non-fasting alternative to OGTT, though it may underestimate glycemia in certain populations (e.g., hemoglobinopathies) . The IDF estimates that 50.1% of adults with diabetes are undiagnosed, highlighting the need for systematic screening in high-risk groups (e.g., BMI ≥25 kg/m², age ≥45 years, or additional risk factors) . The metabolic syndrome’s diagnostic flexibility—requiring three abnormal findings from five components—facilitates early identification of at-risk individuals, though ethnic-specific waist circumference thresholds remain unresolved 0.
Glycemic Control and Complications
Landmark trials demonstrate the benefits of intensive glycemic control. In the Diabetes Control and Complications Trial (DCCT), intensive insulin therapy in type 1 diabetes reduced the risk of retinopathy progression by 54–76% over 6.5 years, with sustained benefits observed during follow-up 1. For type 2 diabetes, the UK Prospective Diabetes Study (UKPDS) showed that each 1% reduction in HbA1c was associated with a 21% decrease in any diabetes-related endpoint, 14% reduction in myocardial infarction, and 37% reduction in microvascular complications 2. The UKPDS 33 trial further confirmed that intensive therapy (targeting FPG <6.0 mmol/L) reduced microvascular risks compared to conventional treatment, though macrovascular benefits were less pronounced 3. However, the ACCORD trial revealed that targeting near-normal HbA1c (≤6.0%) in high-risk type 2 diabetes patients increased mortality, emphasizing the need for individualized targets 4.
Prevention Strategies
Primary prevention of type 2 diabetes is achievable through lifestyle modification. The Diabetes Prevention Program (DPP) demonstrated that a structured program achieving 7% weight loss and 150 minutes/week of physical activity reduced diabetes incidence by 58% over 2.8 years, compared to 31% with metformin 5. The Finnish Diabetes Prevention Study corroborated these findings, with a 58% relative risk reduction in diabetes over 4 years in the intervention group 6. These interventions are cost-effective and scalable, with the DPP estimating that one case of diabetes is prevented for every 6.9 participants treated for 3 years 7.
Pharmacotherapy and Cardiovascular Outcomes
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized diabetes management by reducing cardiovascular and renal events. The EMPA-REG OUTCOME trial showed that empagliflozin reduced the primary composite outcome (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% (HR 0.86, 95% CI 0.74–0.99), with significant reductions in cardiovascular death (38%), heart failure hospitalization (35%), and all-cause mortality (32%) 8. Similarly, canagliflozin in the CANVAS Program reduced the primary outcome by 14% (HR 0.86, 95% CI 0.75–0.97) and slowed renal progression, including a 27% reduction in albuminuria progression 9. These benefits are attributed to mechanisms such as osmotic diuresis, blood pressure reduction, and metabolic effects, independent of glycemic control 7,9.
Global Burden and Projections
The IDF projects a 16% increase in global diabetes prevalence by 2045, with the highest relative growth in middle-income countries (21.1%) 0. This trend is paralleled by rising healthcare expenditures, estimated at $966 billion in 2021, driven by complications and comorbidities 1. The burden is disproportionately borne by low- and middle-income countries, where 80% of diabetes-related deaths occur, and access to care is limited 2. These projections underscore the urgency of implementing cost-effective prevention and management strategies.
Clinical Implications
Clinicians should prioritize early diagnosis using standardized criteria (FPG, OGTT, HbA1c) and screen high-risk individuals annually, particularly in populations with high undiagnosed rates 5,15. For glycemic targets, HbA1c goals should be individualized: <7.0% for most adults, <6.5% for those without hypoglycemia risk, and